Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration.

about

Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration.

Item

http://www.wikidata.org/entity/Q49997422

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Cerebrospinal Fluid Abacavir C ...... ing Once-daily Administration.

@en

Cerebrospinal Fluid Abacavir C ...... ing Once-daily Administration.

@nl

type

Item

label

Cerebrospinal Fluid Abacavir C ...... ing Once-daily Administration.

@en

Cerebrospinal Fluid Abacavir C ...... ing Once-daily Administration.

@nl

prefLabel

Cerebrospinal Fluid Abacavir C ...... ing Once-daily Administration.

@en

Cerebrospinal Fluid Abacavir C ...... ing Once-daily Administration.

@nl

P1476

Cerebrospinal fluid abacavir c ...... wing once-daily administration

@en

P2093

A Antinori

http://www.w3.org/2001/XMLSchema#string

A De Nicolò

http://www.w3.org/2001/XMLSchema#string

C Pinnetti

http://www.w3.org/2001/XMLSchema#string

E Scarvaglieri

http://www.w3.org/2001/XMLSchema#string

G Di Perri

http://www.w3.org/2001/XMLSchema#string

M Gisslen

http://www.w3.org/2001/XMLSchema#string

S Bonora

http://www.w3.org/2001/XMLSchema#string

V Fedele

http://www.w3.org/2001/XMLSchema#string

P2860

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.

UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

P304

1380-1383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13552

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio D'Avolio

Massimo Tempestilli

A Calcagno

P577

2018-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29444348

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

5980549

http://www.w3.org/2001/XMLSchema#string